Free Trial
→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad) Buy CRSP Stock  Free CRSP Stock Alerts

CRISPR Therapeutics (CRSP) Financials

CRISPR Therapeutics logo
$37.57 +0.71 (+1.93%)
Closing price 04:00 PM Eastern
Extended Trading
$37.54 -0.02 (-0.07%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for CRISPR Therapeutics

Annual Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -366 -154 -650 373 -349 67 -165 -68 -23 -26
Consolidated Net Income / (Loss)		 -366 -154 -650 378 -349 67 -165 -68 -23 -26
Net Income / (Loss) Continuing Operations		 -366 -154 -650 378 -349 67 -165 -68 -23 -26
Total Pre-Tax Income 		-363 -151 -651 380 -348 67 -164 -67 -23 -26
Total Operating Income		 -467 -223 -673 374 -354 47 -159 -65 -68 -26
Total Gross Profit		 37 371 1.20 915 0.72 290 3.12 41 5.16 0.25
Total Revenue		 37 371 1.20 915 0.72 290 3.12 41 5.16 0.25
Operating Revenue		 37 371 1.20 915 0.72 290 3.12 41 5.16 0.25
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 504 594 674 541 355 243 162 106 73 26
Selling, General & Admin Expense		 73 76 102 100 86 63 48 36 31 13
Research & Development Expense		 321 387 462 341 221 179 114 70 42 13
Other Operating Expenses / (Income)		 110 130 110 101 48 - - - - -
Total Other Income / (Expense), net		 104 72 23 6.00 6.38 21 -5.49 -1.96 45 -0.09
Other Income / (Expense), net		 104 72 23 6.00 6.38 26 -1.21 -0.20 79 0.02
Income Tax Expense		 3.59 2.89 -0.33 1.87 0.81 0.45 0.55 1.75 0.48 0.01
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.07 -0.07 0.08 4.98 -0.04 -0.02 0.02 -0.04 0.02 0.01
Basic Earnings per Share		 ($4.34) ($1.94) ($8.36) $4.97 ($5.29) $1.23 ($3.44) ($1.71) ($1.89) ($5.06)
Weighted Average Basic Shares Outstanding		 84.36M 79.22M 77.75M 75.95M 65.95M 54.39M 47.96M 40.06M 12.26M 5.04M
Diluted Earnings per Share		 ($4.34) ($1.94) ($8.36) $4.70 ($5.29) $1.17 ($3.44) ($1.71) ($1.89) ($5.06)
Weighted Average Diluted Shares Outstanding		 84.36M 79.22M 77.75M 80.39M 65.95M 56.93M 47.96M 40.06M 12.26M 5.04M
Weighted Average Basic & Diluted Shares Outstanding		 85.77M 80.28M 78.65M 77.07M 75.43M 60.85M 47.96M 40.06M 12.26M 5.04M

Quarterly Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -136 -34 -86 -126 -120 89 -112 -78 -53 -105 -176
Consolidated Net Income / (Loss)		 -136 -37 -86 -126 -117 89 -112 -78 -53 -111 -175
Net Income / (Loss) Continuing Operations		 -136 -37 -86 -126 -117 89 -112 -78 -53 -111 -175
Total Pre-Tax Income 		-135 -37 -85 -125 -116 90 -112 -77 -52 -120 -175
Total Operating Income		 -148 -65 -110 -151 -141 70 -132 -95 -64 -132 -182
Total Gross Profit		 0.87 36 0.60 0.52 0.50 201 0.00 70 100 0.01 0.09
Total Revenue		 0.87 36 0.60 0.52 0.50 201 0.00 70 100 0.01 0.09
Operating Revenue		 0.87 36 0.60 0.52 0.50 201 0.00 70 100 0.01 0.09
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 149 100 111 152 141 132 132 165 164 132 182
Selling, General & Admin Expense		 19 18 17 19 18 16 18 19 22 21 27
Research & Development Expense		 72 82 82 80 76 95 91 102 100 104 117
Other Operating Expenses / (Income)		 58 - 11 52 47 20 23 45 42 6.82 39
Total Other Income / (Expense), net		 14 28 25 26 25 20 21 18 13 11 7.26
Other Income / (Expense), net		 14 28 25 26 25 20 21 18 13 11 7.26
Income Tax Expense		 1.11 0.70 0.88 1.29 0.72 0.23 0.41 0.92 1.32 -9.48 -0.58
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.04 -3.31 -0.08 -0.00 3.47 -0.06 0.05 -0.03 -0.03 -5.32 1.92
Basic Earnings per Share		 ($1.58) ($0.41) ($1.01) ($1.49) ($1.43) $1.12 ($1.41) ($0.98) ($0.67) ($1.40) ($2.24)
Weighted Average Basic Shares Outstanding		 85.94M 84.36M 85.23M 84.92M 81.79M 79.22M 79.41M 79.09M 78.68M 77.75M 78.02M
Diluted Earnings per Share		 ($1.58) ($0.41) ($1.01) ($1.49) ($1.43) $1.12 ($1.41) ($0.98) ($0.67) ($1.40) ($2.24)
Weighted Average Diluted Shares Outstanding		 85.94M 84.36M 85.23M 84.92M 81.79M 79.22M 79.41M 79.09M 78.68M 77.75M 78.02M
Weighted Average Basic & Diluted Shares Outstanding		 86.36M 85.77M 85.35M 85.17M 84.92M 80.28M 79.43M 79.41M 78.94M 78.65M 78.29M

Annual Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -91 177 -716 -246 237 489 217 -76 162 155
Net Cash From Operating Activities		 -143 -260 -496 539 -238 57 -96 -70 -53 59
Net Cash From Continuing Operating Activities		 -143 -260 -496 539 -238 57 -96 -70 -53 59
Net Income / (Loss) Continuing Operations		 -366 -154 -650 378 -349 67 -165 -68 -23 -26
Consolidated Net Income / (Loss)		 -366 -154 -650 378 -349 67 -165 -68 -23 -26
Depreciation Expense		 19 20 24 18 9.18 4.73 3.52 3.02 0.93 0.13
Non-Cash Adjustments To Reconcile Net Income		 48 67 110 116 68 34 55 21 -35 3.11
Changes in Operating Assets and Liabilities, net		 156 -194 20 27 33 -48 11 -25 4.23 82
Net Cash From Investing Activities		 -280 375 -259 -1,035 -541 1.33 -2.77 -8.31 32 -1.15
Net Cash From Continuing Investing Activities		 -280 375 -259 -1,035 -541 1.33 -2.77 -8.31 32 -1.15
Purchase of Property, Plant & Equipment		 -1.90 -9.47 -37 -82 -18 -6.68 -2.77 -7.81 -3.02 -1.15
Acquisitions		 0.00 -2.50 0.00 0.00 - 8.01 - - -0.10 -
Purchase of Investments		 -1,486 -1,066 -1,418 -1,509 -594 0.00 0.00 -0.50 - -
Sale and/or Maturity of Investments		 1,208 1,453 1,196 556 71 0.00 0.00 - - -
Net Cash From Financing Activities		 332 63 39 251 1,016 431 316 2.61 183 97
Net Cash From Continuing Financing Activities		 332 63 39 251 1,016 431 316 2.61 183 97
Issuance of Common Equity		 332 63 39 251 1,016 431 316 - 89 -
Effect of Exchange Rate Changes		 -0.02 0.07 -0.08 -0.01 0.04 0.02 - - - 0.01

Quarterly Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -63 73 -259 -223 318 -139 83 100 132 -286 -2.74
Net Cash From Operating Activities		 -54 -50 -107 -96 110 -96 -40 -133 8.80 -113 -105
Net Cash From Continuing Operating Activities		 -54 -50 -107 -96 110 -96 -40 -133 8.80 -113 -105
Net Income / (Loss) Continuing Operations		 -136 -37 -86 -126 -117 89 -112 -78 -53 -111 -175
Consolidated Net Income / (Loss)		 -136 -37 -86 -126 -117 89 -112 -78 -53 -111 -175
Depreciation Expense		 4.74 4.84 4.74 4.85 4.83 4.90 4.93 4.96 5.05 5.85 5.02
Non-Cash Adjustments To Reconcile Net Income		 22 6.79 15 15 11 14 15 19 20 23 27
Changes in Operating Assets and Liabilities, net		 55 -24 -40 10 210 -204 53 -79 37 -32 37
Net Cash From Investing Activities		 -20 106 -162 -127 -98 -81 121 217 118 -176 87
Net Cash From Continuing Investing Activities		 -20 106 -162 -127 -98 -81 121 217 118 -176 87
Purchase of Property, Plant & Equipment		 -0.21 -0.25 -0.22 -0.71 -0.72 -0.74 -2.12 -3.56 -3.06 -6.19 -6.02
Purchase of Investments		 -206 -267 -409 -476 -334 -368 -245 -187 -266 -494 -326
Sale and/or Maturity of Investments		 186 373 248 350 237 287 370 409 387 325 420
Net Cash From Financing Activities		 11 17 9.64 -0.47 306 39 1.56 17 5.40 2.48 15
Net Cash From Continuing Financing Activities		 11 17 9.64 -0.47 306 39 1.56 17 5.40 2.48 15
Issuance of Common Equity		 11 17 9.64 -0.47 306 39 1.56 17 5.40 2.48 15
Effect of Exchange Rate Changes		 0.04 -0.09 0.08 0.00 -0.01 0.06 -0.05 0.03 0.03 0.12 -0.10

Annual Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 2,242 2,230 2,243 2,752 1,828 1,067 489 271 345 159
Total Current Assets		 1,937 1,908 1,853 2,418 1,717 988 466 248 320 157
Cash & Equivalents		 298 389 212 923 1,169 944 457 240 316 156
Short-Term Investments		 1,606 1,304 1,603 1,456 522 0.00 - - - -
Accounts Receivable		 25 200 0.00 0.31 0.14 0.10 0.09 2.63 3.16 0.34
Prepaid Expenses		 8.31 14 38 38 26 44 9.66 6.00 1.51 0.54
Plant, Property, & Equipment, net		 134 152 164 138 42 31 19 19 21 1.33
Total Noncurrent Assets		 171 170 226 197 69 48 4.12 4.10 3.75 1.26
Long-Term Investments		 0.00 1.97 53 0.00 - - - - - -
Intangible Assets		 0.00 0.02 0.07 0.13 0.18 0.24 0.29 0.34 0.40 0.45
Other Noncurrent Operating Assets		 171 168 173 197 69 48 3.83 0.61 0.20 0.10
Total Liabilities & Shareholders' Equity		 2,242 2,230 2,243 2,752 1,828 1,067 489 271 345 159
Total Liabilities		 310 347 368 352 164 127 97 84 112 124
Total Current Liabilities		 88 109 121 120 94 57 28 15 22 10
Accounts Payable		 15 38 27 15 9.09 5.94 5.07 1.64 4.57 1.58
Accrued Expenses		 41 45 78 91 54 30 21 11 16 8.43
Current Deferred Revenue		 3.85 4.11 0.00 1.01 2.34 0.96 1.30 1.03 1.03 0.00
Current Deferred & Payable Income Tax Liabilities		 0.45 0.44 0.14 0.72 10 0.58 0.40 0.35 0.02 0.08
Other Current Liabilities		 28 21 16 12 19 19 0.12 0.14 0.06 0.06
Total Noncurrent Liabilities		 222 238 246 233 69 70 69 69 90 114
Noncurrent Deferred Revenue		 12 14 12 12 12 12 69 69 90 75
Other Noncurrent Operating Liabilities		 210 224 234 220 58 58 0.24 0.31 0.19 0.28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,932 1,883 1,875 2,399 1,664 939 392 188 233 -29
Total Preferred & Common Equity		 1,932 1,883 1,875 2,399 1,664 939 392 188 233 -29
Total Common Equity		 1,932 1,883 1,875 2,399 1,664 939 392 188 233 -29
Common Stock		 3,296 2,881 2,737 2,601 2,238 1,164 684 313 290 4.82
Retained Earnings		 -1,366 -1,000 -846 -196 -574 -225 -292 -125 -57 -34
Treasury Stock		 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 0.00 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 1.84 1.91 -16 -5.07 -0.08 0.01 -0.01 0.01 -0.03 -0.01

Quarterly Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 2,166 2,256 2,340 2,439 2,087 2,197 2,244 2,353
Total Current Assets		 1,868 1,944 2,010 2,120 1,761 1,860 1,908 1,933
Cash & Equivalents		 235 226 484 707 528 445 344 494
Short-Term Investments		 1,620 1,710 1,517 1,401 1,212 1,323 1,539 1,402
Accounts Receivable		 0.00 0.00 0.00 0.00 0.00 70 0.00 0.05
Prepaid Expenses		 12 8.25 8.79 11 21 21 25 37
Plant, Property, & Equipment, net		 129 139 143 147 156 159 162 166
Total Noncurrent Assets		 169 174 186 172 170 178 174 255
Other Noncurrent Operating Assets		 169 174 175 172 170 173 168 177
Total Liabilities & Shareholders' Equity		 2,166 2,256 2,340 2,439 2,087 2,197 2,244 2,353
Total Liabilities		 337 316 359 355 359 381 389 399
Total Current Liabilities		 119 90 128 119 111 133 147 151
Accounts Payable		 13 16 9.45 16 26 28 45 32
Accrued Expenses		 85 47 92 76 66 90 86 103
Current Deferred Revenue		 3.02 4.48 4.76 4.07 3.50 0.00 0.00 0.00
Current Deferred & Payable Income Tax Liabilities		 1.24 0.84 0.45 1.21 0.18 0.56 0.27 4.27
Other Current Liabilities		 18 22 21 21 15 15 16 12
Total Noncurrent Liabilities		 217 227 231 236 248 248 243 249
Noncurrent Deferred Revenue		 12 12 13 14 16 12 12 12
Other Noncurrent Operating Liabilities		 205 214 218 223 232 236 230 236
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,829 1,940 1,981 2,084 1,728 1,816 1,855 1,954
Total Preferred & Common Equity		 1,829 1,940 1,981 2,084 1,728 1,816 1,855 1,954
Total Common Equity		 1,829 1,940 1,981 2,084 1,728 1,816 1,855 1,954
Common Stock		 3,327 3,258 3,227 3,202 2,824 2,802 2,764 2,712
Retained Earnings		 -1,502 -1,329 -1,243 -1,116 -1,089 -977 -899 -736
Treasury Stock		 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 4.14 11 -2.88 -1.55 -6.80 -8.91 -9.39 -22

Annual Metrics And Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -89.95% 30,885.48% -99.87% 127,154.94% -99.75% 9,169.85% -92.38% 693.90% 1,990.69% 0.00%
EBITDA Growth		 -162.37% 79.10% -257.57% 217.30% -537.27% 149.48% -153.37% -646.75% 144.19% -274.89%
EBIT Growth		 -140.62% 76.83% -271.40% 209.04% -578.28% 145.44% -146.98% -724.59% 140.38% -274.66%
NOPAT Growth		 -109.66% 66.94% -226.78% 249.81% -634.38% 141.73% -145.86% 5.11% -164.80% -288.25%
Net Income Growth		 -138.43% 76.37% -272.16% 208.25% -621.80% 140.52% -141.35% -194.62% 10.17% -87.04%
EPS Growth		 -123.71% 76.79% -277.87% 188.85% -552.14% 134.01% -101.17% 9.52% 62.65% -356.85%
Operating Cash Flow Growth		 45.17% 47.48% -191.98% 326.11% -520.57% 158.89% -37.30% -32.60% -188.95% 1,339.89%
Free Cash Flow Firm Growth		 50.07% 26.65% -240.78% 243.70% -1,554.72% 86.57% -34.06% -69.66% -169.00% 0.00%
Invested Capital Growth		 -84.90% 2,561.61% -65.42% 177.90% -500.53% 93.26% -17.02% 35.82% -3.49% 0.00%
Revenue Q/Q Growth		 -81.60% 118.35% -91.50% 1.39% -99.07% 36.16% -91.16% 272.16% 0.00% 0.00%
EBITDA Q/Q Growth		 -58.14% 61.46% 3.55% -7.58% -67.53% 60,445.31% -43.15% -525.40% 0.00% 0.00%
EBIT Q/Q Growth		 -53.36% 58.17% 3.48% -8.73% -65.49% 1,870.63% -41.98% -418.14% 0.00% 0.00%
NOPAT Q/Q Growth		 -40.37% 47.47% 2.06% -8.80% -50.38% 800.32% -40.98% 28.90% 0.00% 0.00%
Net Income Q/Q Growth		 -52.86% 56.55% 4.51% -8.31% -65.12% 693.03% -40.71% -32.99% 0.00% 0.00%
EPS Q/Q Growth		 -54.45% 56.50% 1.88% -0.84% -72.88% 348.94% -37.60% -144.53% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 24.38% 6.22% -5.83% -0.89% -55.01% 127.35% -16.36% 2.94% -259.65% 0.00%
Free Cash Flow Firm Q/Q Growth		 32.57% -10.60% -7.39% -6.88% -25.66% 67.38% -22.04% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 604.06% 1,655.34% 136.68% -42.83% -15.03% 88.51% 11.88% 29.13% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -920.31% -35.26% -52,281.14% 43.44% -47,131.02% 26.76% -5,013.89% -150.79% 218.96% -10,358.70%
Operating Margin		 -1,250.38% -59.95% -56,190.40% 40.82% -49,295.55% 16.14% -5,087.80% -157.69% -1,319.33% -10,416.60%
EBIT Margin		 -971.93% -40.60% -54,298.83% 41.48% -48,408.34% 25.13% -5,126.54% -158.17% 201.05% -10,410.12%
Profit (Net Income) Margin		 -981.54% -41.38% -54,271.70% 41.28% -48,520.86% 23.09% -5,281.08% -166.74% -449.30% -10,456.68%
Tax Burden Percent		 100.99% 101.92% 99.95% 99.51% 100.23% 99.33% 100.34% 102.63% 102.13% 100.03%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 92.49% 102.67% 102.72% -218.82% 100.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.49% 0.00% 0.67% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -303.26% -160.45% -3,444.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -301.05% -160.58% -3,435.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 284.06% 152.28% 3,413.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.20% -8.17% -30.42% 18.59% -26.80% 10.04% -56.89% -32.50% -17.30% -72.97%
Cash Return on Invested Capital (CROIC)		 -155.73% -345.97% -3,347.07% 1,599.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -16.22% -6.74% -26.05% 16.57% -24.05% 9.36% -42.13% -21.04% 4.12% -16.13%
Return on Assets (ROA)		 -16.38% -6.87% -26.03% 16.49% -24.10% 8.59% -43.40% -22.18% -9.20% -16.20%
Return on Common Equity (ROCE)		 -19.20% -8.17% -30.42% 18.59% -26.80% 10.04% -56.89% -32.50% -13.14% 59.98%
Return on Equity Simple (ROE_SIMPLE)		 -18.96% -8.16% -34.67% 15.74% -20.96% 7.12% -42.07% -36.39% -9.96% 88.77%
Net Operating Profit after Tax (NOPAT)		 -327 -156 -471 372 -248 46 -111 -45 -48 -18
NOPAT Margin		 -875.26% -41.97% -39,333.28% 40.62% -34,506.88% 16.03% -3,561.46% -110.38% -923.53% -7,291.62%
Net Nonoperating Expense Percent (NNEP)		 -2.20% 0.12% -8.43% 0.29% -7.65% 2.92% -15.36% -8.23% 11.21% -13.21%
Return On Investment Capital (ROIC_SIMPLE)		 -16.90% -8.27% -25.12% - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 195.58% 20.52% 8,552.92% 10.90% 11,925.87% 21.92% 1,545.90% 87.43% 601.39% 5,426.32%
R&D to Revenue		 859.34% 104.34% 38,534.64% 37.22% 30,790.26% 61.94% 3,641.90% 170.26% 817.93% 5,090.28%
Operating Expenses to Revenue		 1,350.38% 159.95% 56,290.40% 59.18% 49,395.55% 83.86% 5,187.80% 257.69% 1,419.33% 10,516.60%
Earnings before Interest and Taxes (EBIT)		 -363 -151 -651 380 -348 73 -160 -65 10 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -343 -131 -626 397 -339 77 -157 -62 11 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.74 2.64 1.70 2.42 6.50 3.58 3.78 5.13 3.46 0.00
Price to Tangible Book Value (P/TBV)		 1.74 2.64 1.70 2.42 6.50 3.58 3.78 5.14 3.47 0.00
Price to Revenue (P/Rev)		 90.03 13.40 2,656.64 6.34 15,045.33 11.61 474.62 23.49 156.18 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 15.56 0.00 50.28 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 6.43% 0.00% 1.99% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 51.52 17.51 186.92 168.22 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 39.01 8.83 1,097.00 3.74 12,694.38 8.35 328.44 17.64 95.08 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 8.60 0.00 31.21 0.00 0.00 43.43 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 9.01 0.00 33.23 0.00 0.00 47.29 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 9.20 0.00 52.09 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 6.35 0.00 42.67 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 10.52 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.08
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.08
Financial Leverage		 -0.94 -0.95 -0.99 -1.00 -1.01 -1.05 -1.21 -1.33 -1.63 -3.34
Leverage Ratio		 1.17 1.19 1.17 1.13 1.11 1.17 1.31 1.47 1.88 4.50
Compound Leverage Factor		 1.17 1.19 1.17 1.13 1.11 1.08 1.35 1.50 -4.11 4.52
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 51.99%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 51.99%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 87.47%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -39.46%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.50
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.60
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.50
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.13
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.53
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.13
Altman Z-Score		 6.12 8.89 4.64 11.56 39.64 17.09 8.36 6.67 5.24 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.04% 182.20%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 22.07 17.54 15.30 20.17 18.21 17.29 16.81 17.12 14.56 15.44
Quick Ratio		 21.97 17.41 14.99 19.85 17.93 16.53 16.46 16.70 14.49 15.39
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -168 -336 -458 325 -226 -14 -102 -76 -45 65
Operating Cash Flow to CapEx		 -7,510.47% -2,749.47% -1,333.07% 659.66% -1,298.43% 847.95% -3,470.57% -897.02% -1,752.65% 5,149.74%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.02 0.17 0.00 0.40 0.00 0.37 0.01 0.13 0.02 0.00
Accounts Receivable Turnover		 0.33 0.00 0.00 4,075.56 5.92 3,097.22 2.30 14.18 2.95 0.73
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.26 2.35 0.01 10.18 0.02 11.62 0.17 2.06 0.46 0.19
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 1,100.46 0.00 0.00 0.09 61.68 0.12 158.55 25.74 123.55 500.95
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 1,100.46 0.00 0.00 0.09 61.68 0.12 158.55 25.74 123.55 500.95
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 28 187 7.03 20 -26 -4.35 -64 -55 -86 -83
Invested Capital Turnover		 0.35 3.82 0.09 -317.25 -0.05 -8.42 -0.05 -0.58 -0.06 -0.01
Increase / (Decrease) in Invested Capital		 -159 180 -13 46 -22 60 -9.37 31 -2.90 -83
Enterprise Value (EV)		 1,456 3,277 1,314 3,420 9,127 2,418 1,026 723 491 0.00
Market Capitalization		 3,360 4,972 3,183 5,799 10,818 3,362 1,483 963 807 0.00
Book Value per Share		 $22.64 $23.70 $23.95 $31.35 $23.56 $17.02 $7.56 $4.58 $5.85 ($5.78)
Tangible Book Value per Share		 $22.64 $23.70 $23.95 $31.35 $23.55 $17.01 $7.55 $4.57 $5.84 ($5.87)
Total Capital		 1,932 1,883 1,875 2,399 1,664 939 392 188 233 74
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 38
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 38
Net Debt		 -1,904 -1,696 -1,868 -2,379 -1,690 -944 -457 -240 -316 -118
Capital Expenditures (CapEx)		 1.90 9.47 37 82 18 6.68 2.77 7.81 3.02 1.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -54 106 -83 -81 -68 -13 -18 -5.88 -17 -9.28
Debt-free Net Working Capital (DFNWC)		 1,849 1,799 1,732 2,298 1,622 930 439 234 298 147
Net Working Capital (NWC)		 1,849 1,799 1,732 2,298 1,622 930 439 234 298 147
Net Nonoperating Expense (NNE)		 40 -2.17 179 -5.97 101 -20 54 23 -24 7.82
Net Nonoperating Obligations (NNO)		 -1,904 -1,696 -1,868 -2,379 -1,690 -944 -457 -243 -319 -118
Total Depreciation and Amortization (D&A)		 19 20 24 18 9.18 4.73 3.52 3.02 0.93 0.13
Debt-free, Cash-free Net Working Capital to Revenue		 -145.99% 28.45% -6,961.52% -8.91% -9,453.69% -4.60% -576.18% -14.35% -335.59% -3,755.47%
Debt-free Net Working Capital to Revenue		 4,956.18% 484.71% 144,567.53% 251.12% 225,641.31% 321.30% 14,041.26% 570.47% 5,774.40% 59,386.64%
Net Working Capital to Revenue		 4,956.18% 484.71% 144,567.53% 251.12% 225,641.31% 321.30% 14,041.26% 570.47% 5,774.40% 59,386.64%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.34) ($1.94) ($8.36) $4.97 ($5.29) $1.23 ($3.44) ($1.71) ($1.89) ($5.06)
Adjusted Weighted Average Basic Shares Outstanding		 84.36M 79.22M 77.75M 75.95M 65.95M 54.39M 52.28M 46.98M 39.81M 5.04M
Adjusted Diluted Earnings per Share		 ($4.34) ($1.94) ($8.36) $4.70 ($5.29) $1.17 ($3.44) ($1.71) ($1.89) ($5.06)
Adjusted Weighted Average Diluted Shares Outstanding		 84.36M 79.22M 77.75M 80.39M 65.95M 56.93M 52.28M 46.98M 39.81M 5.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.44) ($1.71) ($1.89) ($5.06)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 85.77M 80.28M 78.65M 77.07M 75.43M 60.85M 47.96M 40.06M 12.26M 5.04M
Normalized Net Operating Profit after Tax (NOPAT)		 -327 -156 -471 372 -248 46 -111 -45 -48 -18
Normalized NOPAT Margin		 -875.26% -41.97% -39,333.28% 40.62% -34,506.88% 16.03% -3,561.46% -110.38% -923.53% -7,291.62%
Pre Tax Income Margin		 -971.93% -40.60% -54,298.83% 41.48% -48,408.34% 23.24% -5,263.38% -162.47% -439.93% -10,453.85%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.80% -1.43%

Quarterly Metrics And Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 71.63% -82.26% 0.00% -99.26% -99.50% 3,353,333.33% -100.00% 44,203.80% 10,538.30% -99.95% -88.59%
EBITDA Growth		 -17.22% -133.63% 24.80% -67.38% -137.79% 182.73% 37.21% 58.33% 72.46% 16.78% -38.95%
EBIT Growth		 -16.42% -140.87% 23.87% -62.88% -123.92% 174.62% 36.19% 57.26% 70.53% 16.34% -37.09%
NOPAT Growth		 -5.57% -165.15% 16.83% -58.85% -118.01% 175.37% 27.40% 48.04% 63.35% 9.72% -41.55%
Net Income Growth		 -16.64% -141.76% 23.37% -62.60% -119.71% 180.80% 35.75% 58.17% 70.39% 21.72% -37.27%
EPS Growth		 -10.49% -136.61% 28.37% -52.04% -113.43% 180.00% 37.05% 59.17% 71.12% 10.26% -34.13%
Operating Cash Flow Growth		 -149.15% 47.92% -168.25% 28.27% 1,147.32% 15.23% 62.12% 6.14% 106.51% -31.72% -29.37%
Free Cash Flow Firm Growth		 6.30% 202.68% 6.70% 66.55% -930.14% -40.53% -36.86% 29.35% 108.88% 46.92% 50.86%
Invested Capital Growth		 -8.00% -84.90% 133.35% -174.11% 30.08% 2,561.61% 37.23% 151.60% -246.24% -65.42% -153.90%
Revenue Q/Q Growth		 -97.58% 5,828.74% 16.44% 2.58% -99.75% 0.00% -100.00% -30.00% 1,666,566.67% -93.62% -40.51%
EBITDA Q/Q Growth		 -309.68% 60.45% 33.21% -8.32% -217.52% 188.45% -48.65% -53.89% 59.11% 32.86% 1.36%
EBIT Q/Q Growth		 -268.43% 56.96% 32.01% -7.99% -229.34% 180.17% -45.46% -48.45% 56.90% 31.45% 2.56%
NOPAT Q/Q Growth		 -129.80% 41.35% 27.19% -7.59% -241.80% 174.88% -39.05% -47.66% 50.98% 27.88% 0.48%
Net Income Q/Q Growth		 -264.49% 56.59% 32.01% -8.42% -230.49% 179.67% -44.27% -46.50% 52.01% 36.65% 6.07%
EPS Q/Q Growth		 -285.37% 59.41% 32.21% -4.20% -227.68% 179.43% -43.88% -46.27% 52.14% 37.50% 6.67%
Operating Cash Flow Q/Q Growth		 -7.83% 53.20% -11.85% -187.09% 214.24% -141.05% 70.09% -1,614.32% 107.76% -7.71% 25.88%
Free Cash Flow Firm Q/Q Growth		 -189.70% 222.05% -200.71% 71.54% 1.71% -10.90% -7.82% -806.28% 116.64% -8.00% 44.33%
Invested Capital Q/Q Growth		 -192.46% 604.06% 112.59% -31.82% -112.93% 1,655.34% -127.97% 224.37% -592.02% 136.68% -212.09%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -15,046.36% -89.01% -13,343.36% -23,264.22% -22,030.56% 46.96% 0.00% -102.65% -46.69% -1,903,416.67% -180,963.83%
Operating Margin		 -17,158.84% -180.97% -18,294.02% -29,257.25% -27,894.25% 34.58% 0.00% -136.03% -64.49% -2,192,350.00% -194,029.79%
EBIT Margin		 -15,593.87% -102.58% -14,130.56% -24,201.35% -22,989.48% 44.52% 0.00% -109.74% -51.75% -2,000,850.00% -186,302.13%
Profit (Net Income) Margin		 -15,722.08% -104.54% -14,276.08% -24,450.29% -23,133.13% 44.41% 0.00% -111.06% -53.07% -1,842,916.67% -185,690.43%
Tax Burden Percent		 100.82% 101.91% 101.03% 101.03% 100.62% 99.74% 100.37% 101.20% 102.55% 92.11% 99.67%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -43.89% 0.00% -743,692.69% 0.00% 131.89% 0.00% -538.80% 0.00% -134,383.80% -233,467.72%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -44.33% 0.00% -743,691.61% 0.00% 130.77% 0.00% -538.22% 0.00% -134,382.92% -233,465.61%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 41.83% 0.00% 741,510.07% 0.00% -124.01% 0.00% 529.94% 0.00% 133,522.80% 232,608.71%
Return on Equity (ROE)		 -19.71% -2.06% -13.07% -2,182.62% -11.03% 7.88% -19.20% -8.86% -25.56% -861.00% -859.01%
Cash Return on Invested Capital (CROIC)		 0.00% -155.73% -6,197.88% 0.00% 0.00% -345.97% 0.00% -1,189.11% 0.00% -3,347.07% 0.00%
Operating Return on Assets (OROA)		 -255.15% -1.71% -1,319.88% -2,157.51% -2,667.51% 7.39% 0.00% -8.01% -2.14% -959.78% -1,014.55%
Return on Assets (ROA)		 -257.25% -1.74% -1,333.47% -2,179.70% -2,684.17% 7.37% 0.00% -8.11% -2.19% -884.02% -1,011.22%
Return on Common Equity (ROCE)		 -19.71% -2.06% -13.07% -2,182.62% -11.03% 7.88% -19.20% -8.86% -25.56% -861.00% -859.01%
Return on Equity Simple (ROE_SIMPLE)		 -21.08% 0.00% -12.35% -13.42% -10.42% 0.00% -20.46% -22.90% -28.25% 0.00% -34.84%
Net Operating Profit after Tax (NOPAT)		 -104 -45 -77 -106 -98 69 -93 -67 -45 -92 -128
NOPAT Margin		 -12,011.19% -126.68% -12,805.81% -20,480.08% -19,525.97% 34.49% 0.00% -95.22% -45.14% -1,534,645.00% -135,820.85%
Net Nonoperating Expense Percent (NNEP)		 -1.62% 0.44% -0.48% -1.08% -0.91% 1.12% -1.05% -0.58% -0.39% -0.87% -2.11%
Return On Investment Capital (ROIC_SIMPLE)		 -5.68% -2.34% - - - 3.69% - - - -4.91% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,230.75% 50.78% 2,893.52% 3,768.09% 3,562.10% 8.19% 0.00% 27.19% 22.36% 352,816.67% 28,724.47%
R&D to Revenue		 8,379.65% 230.19% 13,647.84% 15,505.80% 15,113.49% 47.29% 0.00% 145.08% 99.94% 1,725,916.67% 124,065.96%
Operating Expenses to Revenue		 17,258.84% 280.97% 18,394.02% 29,357.25% 27,994.25% 65.42% 0.00% 236.03% 164.49% 2,192,450.00% 194,129.79%
Earnings before Interest and Taxes (EBIT)		 -135 -37 -85 -125 -116 90 -112 -77 -52 -120 -175
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -130 -32 -80 -120 -111 94 -107 -72 -47 -114 -170
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.60 1.74 2.06 2.32 2.60 2.64 2.09 2.44 1.92 1.70 2.61
Price to Tangible Book Value (P/TBV)		 1.60 1.74 2.06 2.32 2.60 2.64 2.09 2.44 1.92 1.70 2.61
Price to Revenue (P/Rev)		 77.48 90.03 19.73 22.68 19.93 13.40 21.20 26.05 35.48 2,656.64 361.78
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 51.52 514.72 0.00 0.00 17.51 0.00 61.79 0.00 186.92 0.00
Enterprise Value to Revenue (EV/Rev)		 28.23 39.01 10.18 12.73 12.17 8.83 10.97 15.63 16.63 1,097.00 221.76
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -0.94 -1.00 -1.00 -1.01 -0.95 -1.01 -0.98 -1.00 -0.99 -1.00
Leverage Ratio		 1.18 1.17 1.18 1.19 1.19 1.19 1.21 1.19 1.18 1.17 1.16
Compound Leverage Factor		 1.18 1.17 1.18 1.19 1.19 1.19 1.21 1.19 1.18 1.17 1.16
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.01 6.60 7.71 7.80 9.45 9.24 6.15 7.26 5.83 5.42 7.89
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.64 22.07 21.64 15.73 17.81 17.54 15.83 14.00 13.00 15.30 12.81
Quick Ratio		 15.53 21.97 21.55 15.66 17.72 17.41 15.64 13.84 12.83 14.99 12.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -102 114 -93 -31 -109 -111 -100 -93 13 -79 -73
Operating Cash Flow to CapEx		 -26,187.86% -19,697.24% -48,818.72% -13,519.38% 15,222.19% -13,018.02% -1,881.78% -3,748.10% 287.64% -1,830.53% -1,748.68%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.09 0.09 0.12 0.17 0.08 0.07 0.04 0.00 0.01
Accounts Receivable Turnover		 0.00 0.33 0.00 0.00 0.00 0.00 0.00 4.86 0.00 0.00 140.21
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.27 0.26 1.38 1.34 1.76 2.35 1.06 1.05 0.63 0.01 0.10
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 1,100.46 0.00 0.00 0.00 0.00 0.00 75.17 0.00 0.00 2.60
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 1,100.46 0.00 0.00 0.00 0.00 0.00 75.17 0.00 0.00 2.60
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -26 28 4.01 -32 -24 187 -12 43 -35 7.03 -19
Invested Capital Turnover		 -1.50 0.35 -50.59 36.31 -9.24 3.82 -10.90 5.66 -18.33 0.09 1.72
Increase / (Decrease) in Invested Capital		 -1.94 -159 16 -75 10 180 7.14 26 -58 -13 -55
Enterprise Value (EV)		 1,064 1,456 2,066 2,574 3,306 3,277 1,865 2,658 1,668 1,314 3,125
Market Capitalization		 2,919 3,360 4,001 4,586 5,414 4,972 3,604 4,431 3,557 3,183 5,098
Book Value per Share		 $21.33 $22.64 $22.77 $23.33 $25.48 $23.70 $21.76 $23.01 $23.59 $23.95 $25.05
Tangible Book Value per Share		 $21.33 $22.64 $22.77 $23.33 $25.48 $23.70 $21.76 $23.01 $23.58 $23.95 $25.05
Total Capital		 1,829 1,932 1,940 1,981 2,084 1,883 1,728 1,816 1,855 1,875 1,954
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,855 -1,904 -1,936 -2,013 -2,108 -1,696 -1,740 -1,773 -1,889 -1,868 -1,973
Capital Expenditures (CapEx)		 0.21 0.25 0.22 0.71 0.72 0.74 2.12 3.56 3.06 6.19 6.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -107 -54 -82 -119 -107 106 -90 -41 -122 -83 -114
Debt-free Net Working Capital (DFNWC)		 1,748 1,849 1,854 1,883 2,001 1,799 1,649 1,727 1,761 1,732 1,782
Net Working Capital (NWC)		 1,748 1,849 1,854 1,883 2,001 1,799 1,649 1,727 1,761 1,732 1,782
Net Nonoperating Expense (NNE)		 32 -7.90 8.85 21 18 -20 19 11 7.92 18 47
Net Nonoperating Obligations (NNO)		 -1,855 -1,904 -1,936 -2,013 -2,108 -1,696 -1,740 -1,773 -1,889 -1,868 -1,973
Total Depreciation and Amortization (D&A)		 4.74 4.84 4.74 4.85 4.83 4.90 4.93 4.96 5.05 5.85 5.02
Debt-free, Cash-free Net Working Capital to Revenue		 -284.33% -145.99% -40.21% -58.86% -39.56% 28.45% -53.22% -24.32% -121.68% -6,961.52% -810.03%
Debt-free Net Working Capital to Revenue		 4,640.12% 4,956.18% 914.11% 930.93% 736.31% 484.71% 970.17% 1,015.13% 1,756.64% 144,567.53% 12,645.18%
Net Working Capital to Revenue		 4,640.12% 4,956.18% 914.11% 930.93% 736.31% 484.71% 970.17% 1,015.13% 1,756.64% 144,567.53% 12,645.18%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.58) ($0.41) ($1.01) ($1.49) ($1.43) $1.12 ($1.41) ($0.98) ($0.67) ($1.40) ($2.24)
Adjusted Weighted Average Basic Shares Outstanding		 85.94M 84.36M 85.23M 84.92M 81.79M 79.22M 79.41M 79.09M 78.68M 77.75M 78.02M
Adjusted Diluted Earnings per Share		 ($1.58) ($0.41) ($1.01) ($1.49) ($1.43) $1.12 ($1.41) ($0.98) ($0.67) ($1.40) ($2.24)
Adjusted Weighted Average Diluted Shares Outstanding		 85.94M 84.36M 85.23M 84.92M 81.79M 79.22M 79.41M 79.09M 78.68M 77.75M 78.02M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 86.36M 85.77M 85.35M 85.17M 84.92M 80.28M 79.43M 79.41M 78.94M 78.65M 78.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -104 -45 -77 -106 -98 69 -93 -67 -45 -92 -128
Normalized NOPAT Margin		 -12,011.19% -126.68% -12,805.81% -20,480.08% -19,525.97% 34.49% 0.00% -95.22% -45.14% -1,534,645.00% -135,820.85%
Pre Tax Income Margin		 -15,593.87% -102.58% -14,130.56% -24,201.35% -22,989.48% 44.52% 0.00% -109.74% -51.75% -2,000,850.00% -186,302.13%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About CRISPR Therapeutics' Financials

When does CRISPR Therapeutics's financial year end?

According to the most recent income statement we have on file, CRISPR Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has CRISPR Therapeutics' net income changed over the last 9 years?

CRISPR Therapeutics' net income appears to be on an upward trend, with a most recent value of -$366.25 million in 2024, rising from -$25.83 million in 2015. The previous period was -$153.61 million in 2023. See where experts think CRISPR Therapeutics is headed by visiting CRISPR Therapeutics' forecast page.

What is CRISPR Therapeutics's operating income?
CRISPR Therapeutics's total operating income in 2024 was -$466.57 million, based on the following breakdown:
  • Total Gross Profit: $37.31 million
  • Total Operating Expenses: $503.88 million
How has CRISPR Therapeutics revenue changed over the last 9 years?

Over the last 9 years, CRISPR Therapeutics' total revenue changed from $247 thousand in 2015 to $37.31 million in 2024, a change of 15,006.9%.

How much debt does CRISPR Therapeutics have?

CRISPR Therapeutics' total liabilities were at $309.95 million at the end of 2024, a 10.6% decrease from 2023, and a 149.9% increase since 2015.

How much cash does CRISPR Therapeutics have?

In the past 9 years, CRISPR Therapeutics' cash and equivalents has ranged from $155.96 million in 2015 to $1.17 billion in 2020, and is currently $298.26 million as of their latest financial filing in 2024.

How has CRISPR Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, CRISPR Therapeutics' book value per share changed from -5.78 in 2015 to 22.64 in 2024, a change of -491.9%.


Related Companies

This page (NASDAQ:CRSP) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored